Narcolepsy
Narcolepsy is a chronic neurological disorder characterized by the brain's inability to regulate sleep-wake cycles normally. The pathogenesis of narcolepsy is primarily associated with the loss or dysfunction of hypocretin (orexin)-producing neurons in the lateral hypothalamus, leading to instability in the boundaries between wakefulness, rapid eye movement (REM) sleep, and non-REM sleep. This loss is believed to be due to an autoimmune process in genetically predisposed individuals, particularly those carrying the HLA-DQB1*06:02 allele. The disorder manifests clinically with excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotions), sleep paralysis, hypnagogic or hypnopompic hallucinations, and disrupted nocturnal sleep. The health impacts of narcolepsy are profound, affecting cognitive function, psychosocial well-being, occupational performance, and increasing the risk of accidents due to sudden sleep episodes.
Narcolepsy Type 1, previously known as narcolepsy with cataplexy, is characterized by excessive daytime sleepiness in combination with cataplexy, which is a sudden, transient episode of muscle weakness triggered by emotions such as laughter or surprise. NT1 is also associated with low or undetectable levels of cerebrospinal fluid (CSF) hypocretin-1, reflecting the loss of hypocretin-producing neurons. Additional features may include sleep paralysis, hypnagogic hallucinations, and fragmented nighttime sleep. NT1 is often more severe and has an earlier onset compared to Type 2.
Narcolepsy Type 2, formerly referred to as narcolepsy without cataplexy, presents with excessive daytime sleepiness but lacks cataplexy. CSF hypocretin-1 levels are typically normal or only mildly reduced in NT2. Patients may experience other symptoms such as sleep paralysis and hypnagogic hallucinations, but these are less frequent and less severe than in NT1. NT2 may have a later onset and is generally considered a milder form of the disorder.
Secondary narcolepsy arises as a consequence of identifiable brain lesions, such as tumors, strokes, or traumatic injury affecting the hypothalamic region, or as part of other neurological diseases. It is characterized by excessive daytime sleepiness and may be accompanied by symptoms similar to NT1 or NT2, depending on the extent and location of the hypothalamic damage. Secondary narcolepsy may also be associated with additional neurological deficits, reflecting the underlying etiology.
Narcolepsy has an estimated prevalence of approximately 25 to 50 cases per 100,000 individuals globally, although rates may vary by population and diagnostic criteria. The disorder typically has its onset in childhood, adolescence, or early adulthood, with a peak age of onset between 15 and 35 years. Both sexes are affected, with some studies suggesting a slight male predominance. Narcolepsy is frequently underdiagnosed or misdiagnosed, leading to significant diagnostic delays, often spanning several years from symptom onset. The association with the HLA-DQB1*06:02 allele is particularly strong in Type 1 narcolepsy, and familial aggregation has been observed, suggesting a genetic predisposition. Environmental factors, such as streptococcal infections or influenza A (H1N1) vaccination, have been implicated as potential triggers in genetically susceptible individuals.
The diagnosis of narcolepsy is based on a combination of clinical evaluation, detailed patient history, and objective sleep studies. Key diagnostic criteria include chronic excessive daytime sleepiness occurring for at least three months, with or without cataplexy. The gold standard for diagnosis involves overnight polysomnography (PSG) followed by a multiple sleep latency test (MSLT). PSG is used to exclude other causes of hypersomnolence and to document sleep architecture, while MSLT measures the mean sleep latency and the occurrence of sleep-onset REM periods across a series of nap opportunities. A mean sleep latency of less than 8 minutes and two or more sleep-onset REM periods are suggestive of narcolepsy. Measurement of CSF hypocretin-1 levels can be performed in ambiguous cases, with levels below 110 pg/mL being highly specific for Type 1 narcolepsy. Additional diagnostic tools may include actigraphy, sleep diaries, and exclusion of other medical, psychiatric, or sleep disorders that may present with similar symptoms.
Treatment options for narcolepsy include several pharmacological agents. Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate are formulations of oxybate salts used to improve nocturnal sleep quality and reduce symptoms such as cataplexy and excessive daytime sleepiness. Solriamfetol hydrochloride is a wake-promoting agent indicated for the treatment of excessive daytime sleepiness associated with narcolepsy. Pitolisant hydrochloride, also known as tiprolisant hydrochloride, is a histamine H3 receptor inverse agonist that enhances histaminergic neurotransmission to promote wakefulness and decrease daytime sleepiness. Armodafinil, the R-enantiomer of modafinil, is a wakefulness-promoting agent used to manage excessive daytime sleepiness in narcolepsy patients. Gamma-hydroxybutyrate sodium, commonly referred to as sodium oxybate, is administered to reduce cataplexy and improve daytime alertness. Modafinil is another wakefulness-promoting agent frequently prescribed to mitigate excessive daytime sleepiness in narcolepsy. Dexamfetamine sulfate, also known as dexamphetamine hemisulfate or dextroamphetamine sulfate, is a central nervous system stimulant used to enhance alertness and decrease sleep attacks. Chlorimipramine hydrochloride, also known as clomipramine hydrochloride, is a tricyclic antidepressant that may be utilized to manage cataplexy symptoms. Methylphenidate hydrochloride, including its threo and di-threo forms, is a stimulant medication indicated for the treatment of excessive daytime sleepiness in narcolepsy.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
| calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate | ||||
 | solriamfetol hydrochloride (Rec INNM; USAN) | 178429-62-4 (free base) | C10 H14 N2 O2 . Cl H | 230.691 |
 | pitolisant hydrochloride (Prop INNM; USAN); tiprolisant hydrochloride | 362665-56-3 (free base); 903576-44-3 | C17 H26 Cl N O . Cl H | 332.308 |
 | (-)-modafinil; (R)-modafinil; armodafinil (Rec INN; USAN); l-modafinil | 112111-43-0 | C15 H15 N O2 S | 273.35 |
 | gamma-hydroxybutyrate sodium; sodium oxybate | 502-85-2 | C4 H7 O3 . Na | 126.086 |
 | modafinil (Rec INN) | 68693-11-8 | C15 H15 N O2 S | 273.35 |
 | dexamfetamine sulfate; dexamphetamine hemisulfate; dextroamphetamine sulfate | 51-63-8; 51-64-9 (free base) | 2 C9 H13 N . H2 O4 S | 368.491 |
 | chlorimipramine hydrochloride; clomipramine hydrochloride (Rec INNM; USAN; BANM) | 17321-77-6 | C19 H23 Cl N2 . Cl H | 351.313 |
 | (±)-threo-methylphenidate hydrochloride; di-threo-methylphenidate hydrochloride; methylphenidate hydrochloride (USAN; BANM; JAN) | 298-59-9 | C14 H19 N O2 . Cl H | 269.767 |
Make Order
Experimental Scheme
Implementation
Conclusion
